Cardinal Health to manufacture Tamiflu for Roche

Cardinal Health, the leading provider of products and services supporting the health-care industry, has announced that it has signed agreements to manufacture and package Tamiflu for Roche to help meet current and future demand for the influenza medicine.

Under the terms of the manufacturing agreement, Cardinal Health will manufacture 75 mg hard gelatin capsules of Tamiflu on behalf of Roche at one of Cardinal Health's manufacturing sites in Europe. The companies also have arrangements in place for Tamiflu packaging and printed insert production at facilities in the United States.

"Roche has demonstrated global leadership through its commitment to increase production in advance of a possible avian flu outbreak," said Joseph Papa, chairman and CEO of the Pharmaceutical Technologies and Services segment of Cardinal Health. "Cardinal Health's pharmaceutical manufacturing and packaging expertise allows companies like Roche to expand production in a timely manner. This model is vital in preparing for and responding to situations like avian flu, where rapid, cost-effective solutions are critical to success."

The World Health Organization (WHO) advises that stockpiling antivirals in advance is presently the only way to ensure that sufficient supplies are available in the event of a pandemic. Roche has been working closely with WHO and national governments to ensure governments are aware of the importance of stockpiling antivirals before a pandemic occurs. Roche has received and fulfilled pandemic orders for Tamiflu from more than 75 countries worldwide. The magnitude of these orders varies with some countries, France, Finland, Iceland, Ireland, Luxembourg, Netherlands, New Zealand, Norway, Switzerland and UK stockpiling or intending to stockpile adequate Tamiflu to cover 20 to 40 percent of their population. Roche has also donated 5.125 million courses of Tamiflu treatment to the WHO for international rapid response and regional response to a pandemic influenza strain.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine